Skip to main content
OpenTrials
Completed

NCT Number: NCT01607528

Influence of Probiotics on Infections in Cirrhosis

Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived from gram-negative organisms in the gut, can enter the circulation due to increased gut permeability and contributes to neutrophil dysfunction, infection risk and mortality in alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or decrease gut permeability, the investigators hypothesize that probiotic treatment would restore neutrophil function and prevent infection in alcoholic cirrhosis.

The investigators hypothesize that administration of a probiotic mixture in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity.

The aim of this randomised, double-blinded placebo-controlled study is to assess whether food supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients with cirrhosis and decreases the incidence of significant infections.

92 patients with alcoholic cirrhosis will be included according to a sample size calculation from preliminary data. Patients will be randomized in two groups: Group 1 receives a probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria. The recruited patients will be treated for 6 months. Besides routine clinical and laboratory assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will be performed. Furthermore nutritional status and quality of life will be assessed.

Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial flora, nutritional status and quality of life.

If our hypothesis holds true, probiotics will provide an easily applicable and cost effective method to improve immune function and to prevent infection in liver cirrhosis. It is possible that this can improve survival of patients with liver cirrhosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Internal Medicine, Medical University of Geraz

Graz, 8036, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Patients aged between 18-80 years

  • Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis of any cause
  • Informed consent

Exclusion criteria

  • Child-Pugh score > 11
  • Abstinence from alcohol for < 2 weeks at the time of screening for inclusion
  • Clinical evidence of active infection
  • Antibiotic treatment within 7 days prior to enrolment
  • Gastrointestinal haemorrhage within previous 2 weeks
  • Use of immunomodulating agents within previous month (steroids etc.)
  • Use of proton pump inhibitors for preceding two weeks
  • Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study
  • Renal failure (such as hepatorenal syndrome), creatinine >1.7 mg/dL
  • Hepatic encephalopathy II to IV
  • Pancreatitis
  • Other organ failure
  • Hepatic or extra-hepatic malignancy
  • Pregnancy
  • Presumed non-compliance to the study medication

Treatment and study plan

Winclove-849

Dietary Supplement

6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g

Placebo

Dietary Supplement

A similar looking and tasting powder with no active substances

Primary outcomes

  1. Change in neutrophil phagocytic capacity

    Time frame: Change from baseline to 6 months

    Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria

Secondary outcomes

  1. Number of clinically significant infections

    Time frame: during 12 months

    Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months

  2. endotoxin levels

    Time frame: 0, 6, 12 months

    Endotoxin in serum (EU/ml)

  3. neutrophil oxidative burst

    Time frame: 0, 6, 12 months

    percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity

  4. neutrophil toll like receptor expression

    Time frame: 0, 6, 12 months

    percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity

  5. albumin oxidation

    Time frame: 0, 6, 12 months

    oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)

  6. inflammatory response

    Time frame: 0, 6, 12 months

    elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)

  7. bacterial flora

    Time frame: 0, 6, 12 months

    isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate

  8. quality of life

    Time frame: 0, 6, 12 months

    (short form) SF-36 questionaire

  9. nutritional status

    Time frame: 0,6, 12 months

    subjective global assessment

  10. changes in gut permeability over time

    Time frame: 0, 6, 12 months

    elevated lactulose mannitol ratio, elevated zonulin

Sponsors and collaborators

Lead sponsor

Medical University of Graz

Other

Collaborators

  • Austrian Science Fund (FWF)

Registry information

Official study title

Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections

Acronym: PIC

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
May 30, 2012
Registry last updated
May 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.